Isabelle Vanden Bempt

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. ncbi Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas
    I Vanden Bempt
    Department of Pathology, University Hospital of K U Leuven, and Centre for Human Genetics, K U Leuven, Leuven, Belgium
    Histopathology 46:431-41. 2005
  2. ncbi Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes
    Isabelle Vanden Bempt
    Department of Pathology, University Hospital of KU Leuven, Minderbroedersstraat 12, 3000 Leuven, Belgium
    J Pathol 208:486-94. 2006
  3. ncbi The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity
    Isabelle Vanden Bempt
    Department of Pathology, University Hospital of the Katholieke Universiteit Leuven, Leuven, Belgium
    Curr Opin Oncol 19:552-7. 2007
  4. ncbi Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing
    Isabelle Vanden Bempt
    Department of Pathology, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Oncol 26:4869-74. 2008
  5. ncbi Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis
    Vanya Van Belle
    Department of Electrical Engineering, Katholieke Universiteit Leuven, Kasteelpark Arenber, 10 2446, B 3001 Leuven, Belgium
    J Clin Oncol 28:4129-34. 2010
  6. ncbi Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
    Ben Van Calster
    Multidisciplinary Breast Centre, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium
    Breast Cancer Res Treat 113:181-7. 2009
  7. ncbi The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas
    Lieve Verlinden
    Laboratorium voor Experimentele Geneeskunde en Endocrinologie and CMPG ESAT, Katholieke Universiteit Leuven, Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Cancer Res 67:6574-81. 2007
  8. ncbi T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response
    Peter Van Loo
    Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Haematologica 95:440-8. 2010
  9. ncbi In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement
    Patrick Neven
    J Clin Oncol 26:1768-9; author reply 1769-71. 2008

Collaborators

Detail Information

Publications9

  1. ncbi Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas
    I Vanden Bempt
    Department of Pathology, University Hospital of K U Leuven, and Centre for Human Genetics, K U Leuven, Leuven, Belgium
    Histopathology 46:431-41. 2005
    ..To evaluate the HER-2/neu status at the mRNA and DNA level of breast carcinomas and to compare it with HER-2/neu receptor overexpression by immunohistochemistry (IHC)...
  2. ncbi Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes
    Isabelle Vanden Bempt
    Department of Pathology, University Hospital of KU Leuven, Minderbroedersstraat 12, 3000 Leuven, Belgium
    J Pathol 208:486-94. 2006
    ..In addition, using CESH, it was possible to identify an ERBB2 expression signature, comprising four chromosomal regions with potential significance in the aggressive behaviour of ERBB2-positive IDC-NOS...
  3. ncbi The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity
    Isabelle Vanden Bempt
    Department of Pathology, University Hospital of the Katholieke Universiteit Leuven, Leuven, Belgium
    Curr Opin Oncol 19:552-7. 2007
    ..We discuss recent findings on the genotypic alterations associated with HER2-positive breast cancer in an attempt to clarify the clinical heterogeneity observed among these tumors...
  4. ncbi Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing
    Isabelle Vanden Bempt
    Department of Pathology, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Oncol 26:4869-74. 2008
    ..We investigated the impact of polysomy 17 on HER-2 testing and studied its clinicopathologic significance in relation to HER2 gene amplification...
  5. ncbi Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis
    Vanya Van Belle
    Department of Electrical Engineering, Katholieke Universiteit Leuven, Kasteelpark Arenber, 10 2446, B 3001 Leuven, Belgium
    J Clin Oncol 28:4129-34. 2010
    ....
  6. ncbi Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
    Ben Van Calster
    Multidisciplinary Breast Centre, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium
    Breast Cancer Res Treat 113:181-7. 2009
    ..To examine the frequency of axillary lymph node (ALN) invasion of operable breast cancers by their combined oestrogen receptor (ER), progesterone receptor (PR) and HER-2 status...
  7. ncbi The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas
    Lieve Verlinden
    Laboratorium voor Experimentele Geneeskunde en Endocrinologie and CMPG ESAT, Katholieke Universiteit Leuven, Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Cancer Res 67:6574-81. 2007
    ..Further research is warranted to validate the use of Chk1 inhibitors in triple-negative breast carcinomas for which treatment strategies are limited at present...
  8. ncbi T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response
    Peter Van Loo
    Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Haematologica 95:440-8. 2010
    ..The tumor cells of both lymphomas share several characteristics, while the cellular composition of their microenvironment is clearly different...
  9. ncbi In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement
    Patrick Neven
    J Clin Oncol 26:1768-9; author reply 1769-71. 2008